Abstract
RSV is a leading cause of respiratory tract disease in infants and the elderly. RSV has limited therapeutic interventions and no FDA-approved vaccine. Gaps in our understanding of virus–host interactions and immunity contribute to the lack of biological countermeasures. This review updates the current understanding of RSV immunity and immunopathology with a focus on interferon responses, animal modeling, and correlates of protection.
Original language | English |
---|---|
Article number | 2478 |
Pages (from-to) | 1-30 |
Number of pages | 30 |
Journal | Viruses |
Volume | 13 |
Issue number | 12 |
DOIs | |
Publication status | Published - Dec 2021 |
Externally published | Yes |